Figure 1.
Major advance cardiovascular event-free survival curve by ABSORB EXTEND trial and real-world practice (A), and no significant difference was observed (p = 0.65). Major advance cardiovascular event free survival curve by lesion types (B) revealed slight increased events in lesion type B and C (p = 0.31).